Concept
Immune Response
Future of Cancer Science | AACR Cancer Progress Report 2025 / Monitoring Treatment Response and Predicting Resistance
"Early changes in ctDNA levels after starting treatment have also been used to predict treatment outcome and monitor immune response. In a phase II clinical trial, early changes in tumor-agnostic ctDNA features within the first week of starting treatment with the ICI pembrolizumab predicted both progression-free survival and overall survival across solid tumors (1084)Stutheit-Zhao EY, et al. (2024) Cancer Discov, 14: 1048..\n\nTogether, these findings position ctDNA as a critical tool for predicting resistance and assessing treatment effectiveness, with ongoing research also exploring its use in pediatric cancers (1085)Janssen FW, et al. (2024) NPJ Precis Oncol, 8: 172.."
Related Ideas
- KRAS ProfilingFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Kidney MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Recurrence MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- MRD DetectionFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Clinical BarriersFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Risk StratificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Early DiagnosisFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Treatment ResponseFuture of Cancer Science | AACR Cancer Progress Report 2025 · Enhancing Clinical Decision-Making